Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome
June 16, 2023 09:05 ET | Clearmind Medicine Inc.
The treatment combines Clearmind's MEAI, a novel proprietary psychedelic treatment for various addictions, and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of its proprietary...
Jeffs' Brands: SciSparc Nutraceuticals was Granted an Exclusive License for the Sales of CannAmide™ on the Amazon Marketplace in Canada
June 07, 2023 08:05 ET | Jeffs' Brands Ltd
Tel Aviv, Israel, June 07, 2023 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd (the “Company” or “Jeffs' Brands”) (Nasdaq: JFBR), a data-driven e-commerce company operating on the Amazon Marketplace, today...
Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression
April 21, 2023 08:30 ET | Clearmind Medicine Inc.
The application is for a novel psychedelic-based combination, of Clearmind's MEAI and SciSparc's Cannamide™ Tel Aviv, Israel / Vancouver, Canada, April 21, 2023 (GLOBE NEWSWIRE) --...
Jeffs' Brands Entered into a Definitive Agreement to Acquire a 49% interest in a company that Owns Wellution, a Top Seller Brand on Amazon for $2.5 million
February 23, 2023 08:45 ET | Jeffs' Brands Ltd
The food supplements and cosmetics brand is profitable with millions of dollars in gross annual sales Tel Aviv, Israel, Feb. 23, 2023 (GLOBE NEWSWIRE) --  Jeffs' Brands Ltd (the “Company” or...
Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds
February 22, 2023 08:00 ET | Clearmind Medicine Inc.
The company submitted three provisional patent applications with the United States Patent and Trademark Office to protect the novel combination compounds with SciSparc's PEA Tel Aviv, Israel /...
SciSparc Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
November 29, 2022 08:00 ET | SciSparc Ltd
Tel-Aviv, Nov. 29, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the...
SciSparc Gains Competitive Edge with Additional U.S. Patent Granted
November 08, 2022 07:00 ET | SciSparc Ltd
This patent extends protection, adding to six other U.S. patents already granted TEL AVIV, Israel, Nov. 08, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage...
SciSparc Completes the Acquisition of Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million
September 30, 2022 07:00 ET | SciSparc Ltd
Wellution™ offers dozens of products including natural supplements, creams, gels and hemp-based products on Amazon.com Marketplace TEL AVIV, Israel, Sept. 30, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd....
SciSparc Issued Israeli Patent for its Core Technology for Treating Central Nervous Systems Disorders
August 12, 2022 08:00 ET | SciSparc Ltd
Patent extends protection for SciSparc’s novel compounds and methods already granted in the U.S., Australia and Japan TEL AVIV, Israel, Aug. 12, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:...
Clearmind Medicine and SciSparc Collaboration Yields Another Patent Application for Cocaine Addiction Treatment
June 02, 2022 07:48 ET | Clearmind Medicine Inc.
No dedicated treatment currently available for cocaine addiction VANCOUVER, June 02, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the...